Is Maze Therapeutics, Inc. (MAZE) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.2% / 30% | 9.1% / 30% | 0.0% / 30% | 2.78% / 5% | ✓ HALAL |
| DJIM | 1.2% / 33% | 9.1% / 33% | 0.0% / 33% | 2.78% / 5% | ✓ HALAL |
| MSCI | 11.1% / 33% | 81.8% / 33% | 0.0% / 33% | 2.78% / 5% | ✗ NOT HALAL |
| S&P | 1.2% / 33% | 9.1% / 33% | 0.0% / 33% | 2.78% / 5% | ✓ HALAL |
| FTSE | 11.1% / 33% | 81.8% / 33% | 0.0% / 50% | 2.78% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -47.5% | |
| Return on Assets (ROA) | -28.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $76M |
| Free Cash Flow | $75M |
| Total Debt | $27M |
| Debt-to-Equity | 6.6 |
| Current Ratio | 15.5 |
| Total Assets | $241M |
Price & Trading
| Last Close | $31.71 |
| 50-Day MA | $45.48 |
| 200-Day MA | $30.35 |
| Avg Volume | 488K |
|
52-Week Range
$6.71
| |
About Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Purification Calculator
As a halal stock with 2.78% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Maze Therapeutics, Inc. (MAZE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Maze Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Maze Therapeutics, Inc.'s debt ratio?
Maze Therapeutics, Inc.'s debt ratio is 1.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 11.1%.
Does Maze Therapeutics, Inc. require dividend purification?
Yes, Maze Therapeutics, Inc. has an impermissible income ratio of 2.78%, which means 2.78% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Maze Therapeutics, Inc.'s key financial metrics?
Maze Therapeutics, Inc. has a market capitalization of $1.5B, and revenue of $168M. Return on equity stands at -47.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.